Qiagen NV

Type: Company
Name: Qiagen NV
Nationality: Netherlands
Web Address: http://www.qiagen.com/
Fact Sheet: Fact Sheet for Qiagen NV
First reported 12 hours ago - Updated 3 hours ago - 1 reports

AstraZeneca share price: Respiratory portfolio boosted with $2bn deal

iNVEZZ.com, Wednesday, July 30: AstraZeneca Plc (LON:AZN) is boosting its portfolio with a $2 billion (£1.2 billion) deal which will see the Anglo-Swedish drugmaker acquire the rights to Almirall SA’s (BME:ALM) respiratory franchise.The agreement underscores ... [Published Invezz - 12 hours ago]
First reported Jul 29 2014 - Updated 9 hours ago - 4 reports

Qiagen NV's (QGEN) CEO Peer Schatz on Q2 2014 Results - Earnings Call Transcript

OperatorLadies and gentlemen, thank you for standing by. I am Patrick Wright, your Chorus Call operator. Welcome, and thank you for joining Qiagen's Conference Call to discuss results for the Quarter 2 of 2014. [Operator Instructions] Please be advised ... [Published Seeking Alpha - 9 hours ago]
First reported 12 hours ago - Updated 11 hours ago - 1 reports

QIAGEN Crosses Below its 10-day MA (QGEN)

QIAGEN (NASDAQ:QGEN) shares have crossed bearishly below their 10-day moving average of $24.92 on a volume of 530K shares. This may provide swing traders with an opportunity for a short position, as such a crossover often suggests lower prices in the ... [Published Individual.com - 12 hours ago]
First reported Jul 29 2014 - Updated 16 hours ago - 8 reports

Qiagen (QGEN) Showing Bullish Technicals With Resistance At $25.55

The patented option trade-picking algorithms behind MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered call trade on Qiagen NV (QGEN) that includes 6.75% downside protection.Sell one contract of the Nov. '14 $25.00 call ... [Published Market Intelligence Center - 16 hours ago]
First reported Jul 29 2014 - Updated Jul 30 2014 - 3 reports

AstraZeneca, Qiagen Partner For IRESS Companion Test In NSCLC

By Estel Grace MasangkayNetherlands-based sample and assays technologies company Qiagen announced that it has entered into partnership with British pharma giant AstraZeneca for the development and marketing of a liquid biopsy-based companion diagnostic ... [Published Bioresearch Online - Jul 29 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Qiagen NV reaffirms FY 2014 outlook; gives Q3 2014 outlook, revenue outlook above analysts' estimates

9:00pm BSTQiagen NV:Reaffirms FY 2014 expectations to deliver higher adjusted net sales and adjusted earnings.FY 2014 adjusted net sales to rise about 4-5 pct CER, as sales growth of about 8-9 pct CER from the current business portfolio, as well as contributions ... [Published Reuters UK - Jul 29 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Qiagen Q2 profit up on demand for automated testing

9:05pm BSTJuly 29 (Reuters) - German genetic testing specialist Qiagen NV reported a 9 percent rise in second-quarter earnings, slightly above analysts' average forecast, helped by demand for its automated diagnostics gear and for test kits co-developed ... [Published Reuters UK - Jul 29 2014]
First reported Jul 28 2014 - Updated Jul 29 2014 - 2 reports

FTSE LIVE: Footsie rallies after gains by Asian stocks; Reckitt jumps

.30 : The Foosie pushed higher in early deals, recouping around half of Friday’s falls thanks to firmer performances by Asian stock markets, with Reckitt Benckiser the top performer as it unveiled plans to spin-off its pharma unit.In opening deals, the ... [Published Mail Online UK - Jul 28 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 2 reports

Qiagen partners with AstraZeneca on diagnostic companion for gefitinib in NSCLC

Qiagen recently announced a collaboration agreement with AstraZeneca for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with its non–small-cell lung cancer treatment, gefitinib.The project builds on ... [Published Orthopedics Today - Jul 29 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Qiagen GeneRead DNAseq Leukemia V2 gene panel with SF3B1 biomarker

Qiagen has acquired an exclusive global licence to the biomarker SF3B1 from the University of Tokyo. The biomarker is included in the company’s GeneRead DNAseq Leukemia V2 gene panel for next-generation sequencing.SF3B1 is believed to play a critical ... [Published LabOnline - Jul 28 2014]
First reported Jul 25 2014 - Updated Jul 26 2014 - 3 reports

QIAGEN Licenses Blood Cancer Biomarkers

Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers. ... [Published Technology Networks - Jul 26 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 2 reports

Qiagen Adds Cancer Biomarkers to Personalized Healthcare Pipeline

Qiagen has acquired an exclusive global license from the University of Tokyo for the biomarker SF3B1. The company said it sees potential for developing companion diagnostics to guide myelodysplastic syndromes (MDS) treatment with new anticancer compounds ... [Published Genetic Engineering News - Jul 25 2014]

Quotes

"Global Digital Signal Processors (DSP) Market by Intellectual Property (IP), Design Architecture & Applications 2011 - 2016" research report is now available with ReportsnReports.com...
This report studies the "Sample Preparation Market by Product (Instruments (Workstations, Liquid Handling Systems), Consumables (Tubes), Kits (Isolation, Purification), By Application (Genomics, Proteomics), by End Users (Molecular Diagnostics) - Global Forecast to 2018" This market was valued at $4,254.8 million in 2013 and is poised to grow at a CAGR of 5.9% from 2013 to 2018, to reach $5,672.0 million by 2018
...expectations set after having delivered on our targets for the first half of 2014," said Peer M Schatz, Chief Executive Officer of QIAGEN N V "Our five growth drivers are proving a broad base for strong long-term momentum and generating double-digit growth in the first half of 2014. We are expanding the clinically validated and regulated test menu for the QIAsymphony automation workflow, and moving toward 250 new placements in 2014. Personalized Healthcare sales rose on assay sales and new co-development deals, while our QuantiFERON-TB test for latent tuberculosis continues on a growth pace above 20%. In bioinformatics, we added important content to our genomic analysis and interpretation solutions with BIOBASE, the gold standard for hereditary disease analysis. We are also rolling out new universal products for next-generation sequencing, including new gene panels offering the broadest coverage of clinically relevant genes for research in cancer. In addition, our third $100 million share repurchase program is being initiated. We are reaffirming our goals for higher adjusted sales and earnings in 2014."
Mondher Mahjoubi, senior vice president, global product strategy for oncology at AstraZeneca, said, "The use of circulating tumor DNA testing will allow doctors to target the individual needs of each patient quickly and accurately."

More Content

All (424) | News (262) | Reports (1) | Blogs (84) | Audio/Video (0) | Fact Sheets (3) | Press Releases (74)
sort by: Date | Relevance
B7-H3L cell surface antigen and antibodies that... [Published PharmCast - 1 hour ago]
Qiagen NV's (QGEN) CEO Peer Schatz on Q2 2014 R... [Published Seeking Alpha - 9 hours ago]
Hottest Healthcare Stocks Now – AEGR REGN EXAM EW [Published InvestorPlace.com - 11 hours ago]
Common dysregulation network in the human prefr... [Published Molecular Systems Biology - 11 hours ago]
QIAGEN Crosses Below its 10-day MA (QGEN) [Published Individual.com - 12 hours ago]
AstraZeneca share price: Respiratory portfolio ... [Published Invezz - 12 hours ago]
Qiagen Reports In-line Earnings, Beats on Reven... [Published Zacks.com - 12 hours ago]
Global Digital Pathology Market To See 11.8% CA... [Published MoneyShow.com - 13 hours ago]
Recent Study: Sequenom, Inc. (SQNM) - Product P... [Published SBWire - 15 hours ago]
Qiagen (QGEN) Showing Bullish Technicals With R... [Published Market Intelligence Center - 16 hours ago]
Frontrunning: July 30 [Published Zero Hedge - 17 hours ago]
Sample Preparation Market Worth $5,672 Million ... [Published Bradenton Herald - Jul 30 2014]
Qiagen updates guidance after Q2 results [Published Seeking Alpha - Jul 29 2014]
Qiagen NV reaffirms FY 2014 outlook; gives Q3 2... [Published Reuters UK - Jul 29 2014]
Qiagen beats by $0.01, beats on revenue [Published Seeking Alpha - Jul 29 2014]
Qiagen NV (QGEN) Posts Quarterly Earnings, Beat... [Published American Banking News - Jul 29 2014]
QIAGEN Reports Second Quarter and First Half 20... [Published Nasdaq - Jul 29 2014]
Qiagen Q2 profit up on demand for automated tes... [Published Reuters UK - Jul 29 2014]
QIAGEN Reports Second Quarter and First Half 20... [Published KSWO - Jul 29 2014]
QIAGEN Reports Second Quarter And First Half 20... [Published TheStreet.com - Jul 29 2014]
Qiagen Q2 Adj. Profit Rises - Quick Facts [Published RTTNews.com - Jul 29 2014]
QIAGEN Reports Second Quarter and First Half 20... [Published Wall Street Select - Jul 29 2014]
QIAGEN Reports Second Quarter and First Half 20... [Published Eyewitness News - Jul 29 2014]
DGAP-CMS: QIAGEN N.V.: Release of a capital mar... [Published GlobeNewswire: Advertising News - Jul 29 2014]
QIAGEN Reports Second Quarter and First Half 20... [Published PR Newswire: Health - Jul 29 2014]
AstraZeneca, Qiagen Partner For IRESS Companion... [Published Bioresearch Online - Jul 29 2014]
Market Report, "BioTime, Inc. (BTX) - Product P... [Published SBWire - Jul 29 2014]
AstraZenecca Signs Partnership Deals with Roche... [Published Shareprices.com - Jul 29 2014]
Qiagen, AstraZeneca collaborate for lung cancer... [Published Center Watch - Jul 29 2014]
Qiagen partners with AstraZeneca on diagnostic ... [Published Orthopedics Today - Jul 29 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Frontrunning: July 30 [Published Zero Hedge - 17 hours ago]
Fed Decision-Day Guide: QE Tapering to Inflation Debate ( BBG ) Obama says strains over Ukraine not leading to new Cold War with Russia ( Reuters ) Siemens to BP Prepare for Downward Russia Business Spiral ( BBG ) Paying Ransoms, Europe Bankrolls Qaeda ...
QIAGEN Reports Second Quarter and First Half 20... [Published PR Newswire: Health - Jul 29 2014]
VENLO, the Netherlands, July 29, 2014 /PRNewswire/ --Achieved Q2 2014 targets: Adjusted net sales of $331.2 million (+4% CER); adjusted operating income of $81.2 million and 25% operating margin; adjusted EPS of $0.26 CER H1 2014 adjusted net sales rise ...
QIAGEN and AstraZeneca Collaborate to Develop L... [Published PR Newswire: Financial Services - Jul 28 2014]
HILDEN, Germany and LONDON, July 28, 2014 /PRNewswire/ --Collaboration aims to create and commercialize companion diagnostic using genomic data from plasma samples to guide the use of IRESSA  for non-small cell lung cancer patients New blood test will ...
QIAGEN Adds Promising Genomic Biomarkers for As... [Published PR Newswire: Health - Jul 24 2014]
HILDEN, Germany, and MARSEILLE, France, July 24, 2014 /PRNewswire/ --Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including next-generation sequencing (NGS) gene panels, for blood cancers ...
Qiagen (QGEN) Showing Bullish Technicals With R... [Published MarketIntelligenceCenter.com - Jul 24 2014]
Qiagen NV (QGEN) traded between $24.72 and $25.04 before closing at $25.03 Wednesday and presents some attractive trading opportunities today. MarketIntelligenceCenter.com’s patented algorithms selected a Nov. '14 $25.00 covered call for a net debit of ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
DGAP-CMS: QIAGEN N.V.: Release of a capital mar... [Published GlobeNewswire: Advertising News - Jul 29 2014]
Technical Updates, Recognitions and Social Medi... [Published Financial Services - Jul 18 2014]
DGAP-PVR: QIAGEN N.V.: Release according to Art... [Published GlobeNewswire: Advertising News - Jun 11 2014]
DGAP-CMS: QIAGEN N.V.: Release of a capital mar... [Published GlobeNewswire: Acquisitions News - Jun 11 2014]
DGAP-CMS: QIAGEN N.V.: Release of a capital mar... [Published GlobeNewswire: Acquisitions News - Jun 02 2014]
1 2 3 4 5 6 7 8 9 10 ...
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.